Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: Role of the IκB kinase/nuclear factor-κB pathway

Molecular Pharmacology

Volumn 70, Issue 5, 2006, Pages 1812-1821

  Ciucci, Alessandra ^a   Gianferretti, Patrizia ^a   Piva, Roberto ^a,d   Guyot, Thierry ^b,e   Snape, Timothy J ^c   Roberts, Stanley M ^c   Santoro, M Gabriella ^a,f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF TURIN   (Italy)

^e CXR Biosciences Ltd   (United Kingdom)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 TERT BUTYLDIMETHYLSILYLOXY 5 ISO PROPYLMETHYLENECYCLOPENT 2 ENONE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CTC 35; CYCLOPENTENONE DERIVATIVE; DNA FRAGMENT; DOXORUBICIN; ESTROGEN RECEPTOR; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; PACLITAXEL; PROSTAGLANDIN; PROSTAGLANDIN J2; PROTEIN BCL XL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER THERAPY; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARACHIDONIC ACID; BREAST NEOPLASMS; CASPASES; CYCLOPENTANES; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; HUMANS; I-KAPPA B KINASE; INHIBITOR OF APOPTOSIS PROTEINS; NF-KAPPA B; PROSTAGLANDIN D2; RECEPTORS, ESTROGEN; TUMOR CELLS, CULTURED;

EID: 33751161701     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.025759     Document Type: Article

References (40)

1. Amici C, Belardo G, Rossi A, and Santoro MG (2001) Activation of I-κB kinase by herpes simplex virus type 1. A novel target for anti-herpetic therapy. J Biol Chem 276:28759-28766.
2. Amici C, Belardo G, Rozera C, Bernasconi D, and Santoro MG (2004) Inhibition of herpesvirus-induced HIV-1 replication by cyclopentenone prostaglandins: role of IκB kinase (IKK). AIDS 18:1271-1280.
3. Baldwin AS (2001) Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Investig 107:241-246.
4. Bharti AC, Donato N, Singh S, and Aggarwal BB (2003) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101:1053-1062.
5. Bickley JF, Ciucci A, Evans P, Roberts SM, Ross N, and Santoro MG (2004) Reactions of some cyclopentenones with selected cysteine derivatives and biological activities of the product thioethers. Bioorg Med Chem 12:3221-3227.
6. Biswas DK, Cruz AP, Gansberger E, and Pardee AB (2000) Epidermal growth factor-induced nuclear factor κB activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 97:8542-8547.
7. Biswas DK, Martin KJ, McAlister C, Cruz AP, Graner E, Dai SC, and Pardee AB (2003) Apoptosis caused by chemotherapeutic inhibition of nuclear factor-κB activation. Cancer Res 63:290-295.
8. Chen Y, Morrow JD, and Roberts LJ (1999) Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. J Biol Chem 274:10863-10868.
9. Clarke R, Thompson EW, Leonessa F, Lippman J, McGarvey M, Frandsen TL, and Brunner N (1993) Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res Treat 24:227-239.
10. 2-induced apoptosis in breast cancer cells. J Biol Chem 276:47131-47135.
11. Dai Y, Rahmani M, and Grant S (2003) Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene 22:7108-7122.
12. Hengartner MD (2000) The biochemistry of apoptosis. Nature (Lond) 407:770-776.
13. Israel A (2000) The IKK complex: an integrator of all signals that activate NF-kappaB? Trends Cell Biol 10:129-133.
14. Jordan VC (1992) The strategic use of antiestrogens to control the development and growth of breast cancer. Cancer 70:977-982.
15. Karin M and Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-kappaB activity. Annu Rev Immunol 18:621-663.
16. Karin M, Cao Y, Greten FR, and Li ZW (2002) NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301-310.
17. Karin M and Lin A (2002) NF-κB at the crossroad of life and death. Nat Immunol 3:221-227.
18. Li Q and Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2:725-734.
19. Liu JD, Lin SY, Ho YS, Pan S, Hung LF, Tsai SH, Lin JK, and Liang YC (2003) Involvement of c-jun N-terminal kinase activation in 15-deoxy-delta12,14- prostaglandin J2- and prostaglandin A1-induced apoptosis in AGS gastric epithelial cells. Mol Carcinog 37:16-24.
20. Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, Bommert K, and Dorken Bet (2003) Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis. Blood 102:1028-1034.
21. McGuire WL, Chamness GC, and Fuqua SA (1991) Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5:1571-1577.
22. Nakshatri P, Bhat-Nakshatri DA, Martin RJ, Goulet J, and Sledge GW (1997) Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629-3639.
23. Nencioni A, Lauber K, Grunebach F, Van Parijs L, Denzlinger C, Wesselborg S, and Brossart P (2003) Cyclopentenone prostaglandins induce lymphocyte apoptosis by activating the mitochondrial apoptosis pathway independent of external death receptor signaling. J Immunol 171:5148-5156.
24. Padilla J, Kaur K, Cao HJ, Smith TJ, and Phipps RP (2000) Peroxisome proliferator activator receptor-gamma agonists and 15-deoxy-Delta(12,14)(12,14)- PGJ(2) induce apoptosis in normal and malignant B-lineage cells. J Immunol 165:6941-6948.
25. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet RJ Jr, Sledge GW Jr, et al. (2000) Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by Ikappa-Balpha super-repressor and parthenolide. Oncogene 19:4159-4169.
26. 2 induces apoptosis in human malignant B-cells: an effect associated with inhibition of NF-κB activity and down-regulation of anti-apoptotic proteins. Blood 105:1750-1758.
27. Qin C, Burghardt R, Smith R, Wormke M, Stewart J, and Safe S (2003) Peroxisome proliferator-activated receptor γ agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells. Cancer Res 63:958-964.
28. Rayet B and Gelinas C (1999) Aberrant rel/NF-κB genes and activity in human cancer. Oncogene 18:6938-6947.
29. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Traish AM, Mercurio F, and Sonenshein GE (2001) Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-κB in breast cancer. Cancer Res 61:3810-3818.
30. Rossi A, Elia G, and Santoro MG (1996) 2-Cyclopenten-1-one, a new inducer of heat shock protein 70 with antiviral activity. J Biol Chem 271:32192-32196.
31. 1: an effect associated with heat shock transcription factor activation. Proc Natl Acad Sci USA 94:746-750.
32. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, and Santoro MG (2000) Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature (Lond) 403:103-108.
33. Rothwarf DM, Zandi E, Natoli G, and Karin M (1998) IKK-γ is an essential regulatory subunit of the IκB kinase complex. Nature (Lond) 395:297-300.
34. Santoro MG (1997) Antiviral activity of cyclopentenone prostanoids. Trends Microbiol 5:276-281.
35. Santoro MG, Garaci E, and Amici C (1989) Prostaglandins with antiproliferative activity induce the synthesis of a heat shock protein in human cells. Proc Natl Acad Sci USA 86:8407-8411.
36. Santoro MG, Rossi A, and Amici C (2003) NF-κB and virus infection: who controls whom. EMBO (Eur Mol Biol Organ) J 22:2552-2560.
37. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, and Sonenshein GE (1997) Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J Clin Investig 100:2952-2960.
38. Straus DS and Glass CK (2001) Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 21:185-210.
39. Vane J and O'Grady J (1993) Therapeutic Applications of Prostaglandins (Arnold E ed), Hodder & Stroughton Publishers, Sevenoaks, UK.
40. Weldon CB, Burow ME, Rolfe KW, Clayton JL, Jaffe BM, and Beckman BS (2001) NF-kappaB-mediated chemoresistance in breast cancer cells. Surgery 130:143-150.